Dow Falls Over 100 Points; US Consumer Sentiment Declines In August

Jim Cramer: 'You Could Make Some Money With This 5.6% Yield'

Jim Cramer likes Babcock & Wilcox and Smithfield Foods. He also advises taking some profits on BillionToOne, and calls Eton Pharma a winner.

Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

Eton Pharmaceuticals announced record Q2 2026 revenue with product sales of $37.6 million, representing 99% year-over-year growth. The company reported GAAP EPS of $0.35 and non-GAAP EPS of $0.43, with EBITDA of $14.1 million. Additionally, Eton expanded its infantile hemangioma franchise by acquiring U.S. rights to ASN-001, a late-stage product candidate targeting moderate infantile hemangiomas, complementing its existing HEMANGEOL product.

Dow Falls Over 100 Points, Records Weekly Loss: Investor Sentiment Weakens, but Fear Index Remains in ‘Greed’ Zone

The Fear & Greed Index, which measures market sentiment, declined while remaining in the Greed zone. U.S. stocks closed lower, with the Dow Jones falling over 100 points.

Canaccord Genuity Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $68

Canaccord Genuity analyst Gary Nachman maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $60 to $68.

Securities Fraud Investigation Into Innventure, Inc. (INV) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Innventure, Inc. reported disappointing Q2 2026 results on August 13, 2026, missing earnings and revenue consensus estimates significantly and suspending its 2026 guidance for its Accelsius division. The company cited challenges in the AI infrastructure market including power availability and GPU access constraints for smaller companies. The stock fell 55.1% to $1.62 per share on August 14, 2026, prompting a securities fraud investigation.

Innventure Director James Donnally Purchases 225K Shares At An Average Price Of $1.50 Per Share